Hematologic Oncology | Specialty

Melphalan Triplets Elicit Responses, Are Safe in Relapsed/Refractory Multiple Myeloma

March 5th 2021

The triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib demonstrated encouraging clinical activity and was well tolerated in patients with heavily pretreated relapsed/refractory multiple myeloma.

CAR T for R/R DLBCL: Safety/Tolerability

March 5th 2021

Understanding the CAR-T Process: Collection Through Infusion

March 5th 2021

Ixazomib Triplets Show Efficacy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

March 4th 2021

Ixazomib-based triplet regimens as induction therapy elicited higher rates of efficacy compared with ixazomib/dexamethasone alone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma.

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

March 4th 2021

Evolving Field of Acute Lymphoblastic Leukemia

March 4th 2021

Investigational BCMA Targets in RRMM

March 4th 2021

Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM. 

Targeting BCMA and CAR T Therapy in RRMM

March 4th 2021

Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM. 

Blinatumomab Significantly Prolongs EFS in Pediatric Relapsed B-ALL

March 3rd 2021

Treatment with 1 cycle of blinatumomab prior to transplant was found to result in a significant improvement in event-free survival vs standard intensive multidrug chemotherapy in pediatric patients with high-risk, first-relapse B-cell acute lymphoblastic leukemia.

Brown Breaks Down How to Choose the Optimal Frontline Approach for CLL

March 3rd 2021

The treatment paradigm for chronic lymphocytic leukemia has expanded beyond continuous treatment with BTK inhibitors with the addition of the time-limited regimen of venetoclax plus obinutuzumab.

Targeted DNA Sequencing Informs Posttransplant Relapse Rates in MDS

March 3rd 2021

Targeted DNA sequencing prior to transplant can be used to determine which patients with myelodysplastic syndrome are at high risk for posttransplant relapse and should forego reduced-intensity conditioning in lieu of myeloablative conditioning.

Bispecific Antibodies Could Be the Next Big Advance in Oncology

March 3rd 2021

Now, a new type of antibody-based therapy may overcome the limitations of monoclonal antibodies, and it has the potential to disrupt the current treatment paradigm in oncology.

Therapeutic Considerations in Polycythemia Vera

March 3rd 2021

Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.

Diagnosis and Evaluation in Polycythemia Vera

March 3rd 2021

Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.

Dr. D'Angelo on Novel Therapeutics Under Exploration in DLBCL

March 3rd 2021

Christopher R. D’Angelo, MD, discusses novel therapeutics under investigation in patients with diffuse large B-cell lymphoma.

Novel Combination Therapies Show Promise in Managing Early Relapse in Multiple Myeloma

March 2nd 2021

There is building evidence that novel combination therapies could be effective in treating early relapsed multiple myeloma.

Genotyping Offers Insights Into Key Characteristics of ALL Subtypes

March 2nd 2021

Genomic sequencing is a critical step in informing the prognosis of patients with acute lymphoblastic leukemia and more information regarding specific subgroups of ALL, such as lineage ambiguous ALL, could pave the way for more personalized therapies for patients.

Armand Reviews Novel Therapeutics in Relapsed/Refractory Follicular Lymphoma

March 2nd 2021

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

Investigative Interventions Gain Ground in GVHD

March 2nd 2021

With an increased understanding of disease biology, several approaches are under examination to optimize the management of patients with graft-versus-host disease.

Zanubrutinib Approved in Canada for Waldenström Macroglobulinemia

March 2nd 2021

Health Canada has approved the BTK inhibitor zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.